On November 2, 2023, Matthew Wakefield, the Non-Executive Chairman of Oxford BioDynamics Plc, transferred 94,000 ordinary shares of the company into his ISA. The transfer was made through a sale of 94,000 ordinary shares at a price of 33.75p and the repurchase of 94,000 ordinary shares at a price of 33.80p. Additionally, Wakefield transferred 200,000 ordinary shares to his wife, Carla Wakefield, for no consideration. After these transactions, Matthew Wakefield remains beneficially interested in a total of 1,022,727 ordinary shares, representing approximately 0.70% of the company's current issued share capital.
Oxford BioDynamics Plc is a global biotechnology company that develops and commercializes precision medicine tests for life-changing diseases. Its flagship products include the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch PSE (EpiSwitch Prostate Screening test) blood tests. The CiRT test is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments, while the PSE test boosts the predictive accuracy of a PSA test for prostate cancer. The company has also launched the EpiSwitch CST (Covid Severity Test) and the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics has partnered with big pharma companies and leading institutions and has a valuable technology portfolio in the field of 3D genomics. The company is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange.